Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05600114 |
Recruitment Status :
Active, not recruiting
First Posted : October 31, 2022
Last Update Posted : September 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Social Anxiety Disorder | Drug: Cannabidiol oral solution Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 225 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study, Evaluating the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution in Subjects With Social Anxiety Disorder |
Actual Study Start Date : | October 27, 2022 |
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | December 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Cannabidiol (CBD) Oral Solution 300 mg/day |
Drug: Cannabidiol oral solution
CBD 150 mg BID |
Experimental: Cannabidiol (CBD) Oral Solution 600 mg/day |
Drug: Cannabidiol oral solution
CBD 300 mg BID |
Placebo Comparator: Placebo Oral Solution |
Drug: Placebo
Placebo BID |
- Mean change from baseline to endpoint in the Liebowitz Social Anxiety Scale (LSAS) [ Time Frame: 10 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinically predominant diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) SAD
- LSAS score of 70 or higher
- Females of childbearing potential must test negative for pregnancy and agree to use a reliable birth control method. Male subjects must also agree to use highly effective methods of contraception.
- Read, understand, and sign the informed consent form.
- No significant physical health abnormalities based on physical exam, ECG and laboratory tests.
Exclusion Criteria:
- Other current psychiatric disorder as the clinically predominant diagnosis.
- Lifetime diagnosis of schizophrenia or any other psychosis, MDD with psychotic features, intellectual disability, autism spectrum disorders, bipolar disorder type 1, and cannabis use disorder
- Previous 6 months diagnosis of Post-traumatic stress disorder, obsessive compulsive disorder, moderate to severe alcohol use disorder, and substance abuse disorder (except tobacco use disorder or mild alcohol use disorder)
- Severe MDD
- Use of oral psychoactive medications or beta adrenergic antagonists in the past 4 weeks, or depot neuroleptics within 12 weeks
- Electroconvulsive therapy within 6 months, psychotherapy or transcranial magnetic stimulation within 3 months
- Clinically significant abnormality or clinically significant unstable medical condition
- Impaired liver function
- Significant risk of suicide or homicide
- Pregnancy/lactation
- Sensitivity to CBD or excipients
- Current cannabis use; past frequent cannabis use
- Illegal drug use
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05600114
United States, California | |
EPI-CBD-001 Site | |
Encino, California, United States, 91316 | |
EPI-CBD-001 Site | |
Lemon Grove, California, United States, 91945 | |
EPI-CBD-001 Site | |
Los Alamitos, California, United States, 90720 | |
EPI-CBD-001-Site | |
Oceanside, California, United States, 92056 | |
EPI-CBD-001 site | |
San Jose, California, United States, 95124 | |
United States, Florida | |
EPI-CBD-001 Site | |
Jacksonville, Florida, United States, 32256 | |
EPI-CBD-001 Site | |
Lauderhill, Florida, United States, 33319 | |
EPI-CBD-001 Site | |
Maitland, Florida, United States, 32751 | |
EPI-CBD-001 Site | |
Orlando, Florida, United States, 32801 | |
United States, Illinois | |
EPI-CBD-001 Site | |
Chicago, Illinois, United States, 60640 | |
United States, New York | |
EPI-CBD-001 Site | |
Cedarhurst, New York, United States, 11516 | |
EPI-CBD-001-Site | |
New York, New York, United States, 10036 | |
EPI-CBD-001-Site | |
Rochester, New York, United States, 10036 | |
United States, Oklahoma | |
EPI-CBD-001 Site | |
Oklahoma City, Oklahoma, United States, 73106 | |
United States, Oregon | |
EPI-CBD-001 Site | |
Portland, Oregon, United States, 97210 | |
United States, Texas | |
EPI-CBD-001 site | |
Wichita Falls, Texas, United States, 76309 | |
United States, Washington | |
EPI-CBD-001 Site | |
Bellevue, Washington, United States, 98007 |
Responsible Party: | EmpowerPharm Inc. |
ClinicalTrials.gov Identifier: | NCT05600114 |
Other Study ID Numbers: |
EPI-CBD-001 |
First Posted: | October 31, 2022 Key Record Dates |
Last Update Posted: | September 21, 2023 |
Last Verified: | September 2023 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Anxiety Disorders Phobia, Social Mental Disorders Phobic Disorders |
Cannabidiol Pharmaceutical Solutions Anticonvulsants |